Lilly's U.S. president says most new Bridge users are new to incretins, while oral Foundayo brought in $184 million in Q3, short of Citi's expectations.
Recap by typeshit. Full story at Fierce Pharma.
Obesity specialist Dr. Alexandra Sowa says long-term use makes cost the flashpoint, as insurers and employers scale back coverage and Medicare benefits face a 2027 question.
With 30% of covering employers weighing cuts, Wegovy and Zepbound users should check their plans now. Includes current self-pay prices and tips for appeals.
Endpoints News
Endpoints News reports Lilly's direct-to-patient sales model, built on Americans paying hundreds a month, is now becoming part of its plans overseas.
West Pharmaceutical shares are up about 20% since CNBC flagged the valuation in August, and the latest earnings give it reasons to expect further gains.
Strong sales of its obesity injections pushed Lilly past profit expectations, and the drugmaker raised its full-year outlook, Reuters reports.
Ricks describes working with the Trump administration to lower obesity drug costs for older Americans, on the day Lilly posted third-quarter earnings.
Loading…